Skip to Content

Posts tagged with "Cancer"

  • Cancer

    More Details on T-Cell Leukemia Therapy

    There’s an excellent overview at Science of the work of David Porter and Carl June at the University of Pennsylvania on T-cell-based cancer therapy. It turns out that when the dramatic reports came out on their first three patients, the team was out of funding and trying to see if they could get someone interested. Read More
  • Cancer

    A Specific Crowdfunding Example

    I mentioned Microryza in that last post. Here’s Prof. Michael Pirrung, at UC Riverside, with an appeal there to fund the resynthesis of a compound for NCI testing against renal cell carcinoma. It will provide an experienced post-doc’s labor for a month to prepare an interesting natural-product-derived proteasome inhibitor that the NCI w… Read More
  • Cancer

    The Medical Periodic Table

    Here’s the latest “medical periodic table”, courtesy of this useful review in Chemical Communications. Element symbols in white are known to be essential in man. The ones with a blue background are found in the structures of known drugs, the orange ones are used in diagnostics, and the green ones are medically useful radioisotopes… Read More
  • Cancer

    Aveo Gets Bad News on Tivozanib

    The kinase inhibitor tivozanib (for renal cell carcinoma) was shot down this morning at an FDA committee hearing. There are going to be a lot of arguments about this decision, because feelings have been running high on both sides of the issue. And this has been an issue for over a year now. As that… Read More
  • Cancer

    Costing Just Too Much

    There’s been a lot of rumbling recently about the price of new cancer drugs (see this article for a very typical reaction). It’s a topic that’s come up around here many times, as would be only natural – scrolling back in this category will turn up a whole list of posts. I see that Bernard… Read More
  • Cancer

    Watching PARP1 Inhibitors Fail To Work, Cell By Cell

    Here’s something that’s been sort of a dream of medicinal chemists and pharmacologists, and now can begin to be realized: single-cell pharmacokinetics. For those outside the field, you should know that we spend a lot of time on our drug candidates, evaluating whether they’re actually getting to where we want them to. And thereR… Read More
  • Cancer

    Cancer: Back to N-of-One

    From Nature comes this news of an effort to go back to oncology clinical trials and look at the outliers: the people who actually showed great responses to otherwise failed drugs. By all rights, Gerald Batist’s patient should have died nine years ago. Her pancreatic cancer failed to flinch in the face of the standard… Read More
  • Biological News

    Super-Enhancers in Cell Biology: ENCODE’s Revenge?

    I’ve linked to some very skeptical takes on the ENCODE project, the effort that supposedly identified 80% of our DNA sequence as functional to some degree. I should present some evidence for the other side, though, as it comes up, and some may have come up. Two recent papers in Cell tell the story. The… Read More
  • Cancer

    Stealing A Compound, To Set Up in China

    Here’s a strange case worth keeping an eye on. Via Deborah Blum‘s Twitter feed we have this report of a researcher in Wisconsin being charged with economic espionage – specifically, investigational oncology. Huajun Zhao, 42, faces a single count of economic espionage, according to a federal criminal complaint, an offense punishabl… Read More
  • Cancer

    Novartis Loses the Glivec Patent Fight in India

    This story is all over the news today, but it’s my impression that most of the stories leave out crucial details. This is not just a big multinational drug company being put in its place by Indian courts, nor is it some crazy ruling with no basis in fact. Here’s the story, as best I… Read More
...181920...